S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:CNTA

Centessa Pharmaceuticals (CNTA) Stock Price, News & Analysis

$11.10
+0.34 (+3.16%)
(As of 03/27/2024 ET)
Today's Range
$10.39
$11.23
50-Day Range
$7.46
$12.20
52-Week Range
$3.52
$12.45
Volume
68,643 shs
Average Volume
214,648 shs
Market Capitalization
$1.08 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Centessa Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
9.9% Downside
$10.00 Price Target
Short Interest
Healthy
2.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Centessa Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$642,344 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.63) to ($1.79) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.64 out of 5 stars

Medical Sector

870th out of 939 stocks

Pharmaceutical Preparations Industry

392nd out of 429 stocks

CNTA stock logo

About Centessa Pharmaceuticals Stock (NASDAQ:CNTA)

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

CNTA Stock Price History

CNTA Stock News Headlines

Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Centessa Pharmaceuticals PLC ADR
Centessa Pharmaceuticals PLC ADR (CNTA)
CBOE shift unlocks new weekend income strategy
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend.
7 Biotech Stocks Ready to Ride the Sector's Resurgence
CNTA Apr 2024 7.500 put
CNTA Apr 2024 5.000 call
CNTA Jul 2024 7.500 put
CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals Unveils Clinical Data Online
See More Headlines
Receive CNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2021
Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CNTA
Fax
N/A
Employees
75
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$15.00
Low Stock Price Target
$5.00
Potential Upside/Downside
-9.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-216,210,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.55 per share

Miscellaneous

Free Float
86,363,000
Market Cap
$1.08 billion
Optionable
Optionable
Beta
1.37
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Saurabh Saha M.D. (Age 48)
    Ph.D., CEO & Director
    Comp: $957.67k
  • Dr. Gregory M. Weinhoff M.B.A. (Age 53)
    M.D., Principal Accounting Officer & CFO
    Comp: $655k
  • Dr. David M. Chao Ph.D. (Age 56)
    Chief Administrative Officer
    Comp: $655k
  • Ms. Tia L. Bush (Age 53)
    Chief Technology & Quality Officer
  • Ms. Kristen K. Sheppard Esq.
    J.D., Senior Vice President of Investor Relations & Corporate Communications
  • Mr. Iqbal J. Hussain L.L.B. (Age 43)
    General Counsel, Chief Compliance Officer & Corporate Secretary
  • Ms. Karen M. Anderson (Age 56)
    Chief People Officer
  • Dr. Antoine Yver M.D. (Age 66)
    M.Sc., Executive VP & Chairman of Development
    Comp: $449.58k
  • Dr. Harris L. Rotman Ph.D.
    Senior Vice President of Regulatory Affairs
  • Dr. Patrick Yue M.D.
    Senior VP of Clinical Development & Innovative Medicines

CNTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Centessa Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Centessa Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CNTA shares.
View CNTA analyst ratings
or view top-rated stocks.

What is Centessa Pharmaceuticals' stock price target for 2024?

7 equities research analysts have issued 1 year price targets for Centessa Pharmaceuticals' stock. Their CNTA share price targets range from $5.00 to $15.00. On average, they anticipate the company's share price to reach $10.00 in the next year. This suggests that the stock has a possible downside of 9.9%.
View analysts price targets for CNTA
or view top-rated stocks among Wall Street analysts.

How have CNTA shares performed in 2024?

Centessa Pharmaceuticals' stock was trading at $7.96 on January 1st, 2024. Since then, CNTA shares have increased by 39.4% and is now trading at $11.10.
View the best growth stocks for 2024 here
.

When is Centessa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our CNTA earnings forecast
.

How were Centessa Pharmaceuticals' earnings last quarter?

Centessa Pharmaceuticals plc (NASDAQ:CNTA) issued its quarterly earnings results on Sunday, November, 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.10.

When did Centessa Pharmaceuticals IPO?

Centessa Pharmaceuticals (CNTA) raised $285 million in an initial public offering on Friday, May 28th 2021. The company issued 15,000,000 shares at $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers.

Who are Centessa Pharmaceuticals' major shareholders?

Centessa Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BVF Inc. IL (8.99%), Price T Rowe Associates Inc. MD (2.60%), Price T Rowe Associates Inc. MD (2.60%), Octagon Capital Advisors LP (2.11%), Franklin Resources Inc. (1.14%) and Affinity Asset Advisors LLC (0.82%). Insiders that own company stock include (Bermuda) Ltd Gap, Aaron Kantoff, Antoine Yver, David J Grainger, David M Chao, Gregory M Weinhoff, Harris Rotman, Iqbal J Hussain, Karen M Anderson, Medicxi Ventures Management (J, Rubertis Francesco De, Saurabh Saha, Thomas Templeman and Tia L Bush.
View institutional ownership trends
.

How do I buy shares of Centessa Pharmaceuticals?

Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNTA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners